Bronchitol (Mannitol) Patent Expiration, LOE Window & CMS Spending
Bronchitol (Mannitol) by Pharmaxis Europe: FDA Orange Book LOE 2027-10-30, 0 AB generics, $250K 2024 CMS Part D & Medicaid spend, and $3,656 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pharmaxis Europe |
| FDA Application & Pathway | N202049 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-10-30 |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $250K |
| 2024 Medicare Part D Spend | $126K |
| 2024 Medicaid Spend | $124K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($3,656 intro WAC) |